U.S. Markets open in 8 hrs 56 mins
  • S&P Futures

    3,398.75
    +5.25 (+0.15%)
     
  • Dow Futures

    27,624.00
    +43.00 (+0.16%)
     
  • Nasdaq Futures

    11,500.25
    +8.00 (+0.07%)
     
  • Russell 2000 Futures

    1,606.20
    +4.10 (+0.26%)
     
  • Crude Oil

    38.75
    +0.19 (+0.49%)
     
  • Gold

    1,909.60
    +3.90 (+0.20%)
     
  • Silver

    24.56
    +0.14 (+0.57%)
     
  • EUR/USD

    1.1830
    +0.0017 (+0.1420%)
     
  • 10-Yr Bond

    0.8010
    -0.8410 (-100.00%)
     
  • Vix

    32.46
    -27.55 (-100.00%)
     
  • GBP/USD

    1.3034
    +0.0013 (+0.1030%)
     
  • USD/JPY

    104.7330
    -0.1020 (-0.0973%)
     
  • BTC-USD

    13,108.30
    +6.11 (+0.05%)
     
  • CMC Crypto 200

    261.25
    -2.16 (-0.82%)
     
  • FTSE 100

    5,792.01
    -68.27 (-1.16%)
     
  • Nikkei 225

    23,399.36
    -94.98 (-0.40%)
     

Adicet Bio to Present at the Jefferies Cell Therapy Summit

Adicet Bio
·1 min read

MENLO PARK, Calif. and BOSTON, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that Chen Schor, President and Chief Executive Officer of Adicet Bio, and Stewart Abbot, Ph.D., Chief Scientific and Operating Officer of Adicet Bio, will participate in a fireside chat at the Jefferies Cell Therapy Summit on Monday, October 5, 2020 at 2:30 PM ET.

A live audio webcast of the fireside chat can be accessed on the Investors section of Adicet Bio’s website at https://investor.adicetbio.com. An archived replay will be available for 30 days following the presentation.

About Adicet Bio, Inc.
Adicet Bio, Inc. is a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. For more information, please visit our website at http://www.adicetbio.com.

Adicet Bio, Inc.
Investor and Media Contacts

Anne Bowdidge
abowdidge@adicetbio.com

Janhavi Mohite
Stern Investor Relations, Inc.
212-362-1200
janhavi.mohite@sternir.com